II. Indications

  1. Metastatic Breast Cancer (refractory)
  2. Metastatic Liposarcoma (refractory, non-resectable)

III. Mechanism

  1. See Mitotic Inhibitor Chemotherapy
  2. Eribulin is a Halichondrin B analog with antineoplastic properties
    1. Dervied from the marine sponge Lissodendoryx.
  3. Eribulin is an anti-tubulin agent
    1. Binds to tubulin (at vinca doman)
    2. Inhibits tubulin polymerization and microtubule assembly
    3. Arrests cell cycle at G2/M phase

IV. Medications

  1. Eribulin 1 mg/2ml intravenous solution

V. Dosing

  1. See other references for disease specific dosing protocols
  2. Adjust dosing in renal and hepatic Impairment
  3. Adults: 1.4 mg/m2 on days 1 and 8, in every 21 day cycles

VII. Pharmacokinetics

  1. Hepatic excretion in feces unchanged

VIII. Safety

  1. Avoid in Lactation
  2. Avoid in pregnancy (all trimesters)
    1. Use reliable Contraception

Images: Related links to external sites (from Bing)

Related Studies